Full-Time

Senior Manager – Commercial Performance Optimization Technical Lead

Updated on 9/3/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Pennsylvania, USA

Remote

Remote within the United States; travel 10-20%.

Bachelor's

Category
Data & Analytics
Required Skills
Agile
Data Governance

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor's degree in computer science, engineering, information systems, or related technical field.
  • 7+ years of experience after Bachelor's degree (or 5+ years of experience after Master's degree) in delivering performance optimization, promotional analytics, or marketing effectiveness solutions in pharma or life sciences, including hands-on ownership of MMM or comparable optimization frameworks.
  • 2+ years of experience as a Tech Lead, Technical Program Manager, Engineering Manager, or other roles involving managing a team of developers. Experience as a Tech Lead, or similar role involving hands-on technical leadership of a development team, with experience leading teams working on enterprise analytics platforms, reporting solutions, and cloud data environments.
  • 2+ years of experience designing and delivering enterprise-scale digital platforms such as marketing mix modeling (MMM) solutions, experimentation and optimization approaches, and KPI-driven analytics systems, including hands-on experience using analytics tools and technologies.
  • Experience working within complex, matrixed organizations with multiple technology and capability teams.
  • Proven ability to mentor and guide developers and vendor partners to deliver high-quality solutions.
Responsibilities
  • Partner closely with the Performance Optimization Global Capability Owner to design solutions that solve business problems, providing technical insight on what technology can and cannot do, effort levels, and tradeoffs.
  • Collaborate with the Advanced Analytics & Optimization Technical Suite Lead and Data Architect to translate technology roadmaps into scalable technology architectures and development plans while assessing feasibility, constraints, dependencies, and risks.
  • Convert complex business requirements into clear technical specifications and executable technical work tasks.
  • Lead the technical team and drive work plans, building, configuration, and integration of software aligned to business needs and technology standards, including: Marketing Mix Modeling (MMM) Solutions, in-house advanced analytics models that quantify channel contribution, incremental impact, and optimize marketing investment allocation; Global Reporting & Dashboard capabilities, standardized dashboards and reporting solutions that provide consistent, decision-ready performance insights across brands and channels; Global KPI Frameworks, governed measurement structures that ensure consistent performance tracking and metric definitions across the organization.
  • Translate technical requirements into well‑defined work for the development team, lead agile ceremonies, and ensure disciplined execution of the roadmap, taking ownership of complex technical challenges end to end.
  • Guide development teams in building scalable and compliant global analytics and reporting solutions supporting performance measurement and investment decision-making.
  • Ensure consistent implementation of global KPI frameworks, standardized data models, and governed reporting structures across dashboards and analytics solutions.
  • Support integration of analytics and reporting platforms with upstream data sources (e.g., marketing, customer, and engagement data) and downstream consumption and activation systems.
  • Enable seamless access to insights through standardized, self-service dashboards and global analytics tools.
  • Drive development of automated reporting pipelines and reusable analytics assets to reduce manual reporting and scale insights delivery while ensuring data governance, metric consistency, and quality control across dashboards, reporting solutions, and analytics outputs.
  • Partner with business, IT security, and vendor teams to ensure the Performance Optimization team‘s technical solutions adhere to organizational standards, security policies, and regulatory requirements.
  • Organize and direct vendor partners to execute technical work, ensuring alignment with team priorities, delivery timelines, and global standards.
  • Partner with the Technical Suite Lead, Advanced Analytics & Optimization to escalate and resolve complex technical challenges that span across teams or suites.
  • Mentor and guide software engineers and developers, elevating the team's overall technical capability.
  • Lead cross-team problem solving and resolution of technical challenges within the Global Capability team.
Desired Qualifications
  • Experience in pharmaceutical or healthcare industries preferred.
  • Experience partnering with enterprise platform teams or Global Capability teams supporting digital and operational capabilities.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.